Logo
J

Juno Therapeutics, Inc.

212 employees

Juno Therapeutics is a clinical-stage company, develops immunotherapies for the treatment of cancer.

Investor insights

Sectors invested in

Biotechnology3
Health Care3
Therapeutics2
In Vivo (in body) Editing1
Ocular Medicines1
Blood Diseases1
Cancer1
Immunogenetics1
Sickle Cell Disease1
Rare Diseases1
Medical1
Engineered Cell Medicines1
Hematopoietic Stem Cells1
Genetic Diseases1
Transfusion-Dependent Beta Thalassemia1
Genetics1
Genome Editing1

Funding rounds participated in

$90M sweet spot round size

Most of their 3 investments are in rounds between $47M and $90M

Basic info

Industry

biotechnology research

Sectors

Clinical Trials
Biotechnology
Immunotherapy
Therapeutics
Medical
Health Care
cell therapy

Date founded

2013

Investments made

J

JW Therapeutics 药明巨诺 raised $100M on June 11, 2020

Investors: Mirae Asset MAPS Global Investments Co., Ltd, Temasek, Loyal Valley Capital, CITIC Private Equity Funds Management, ARCH Venture Partners, WuXi AppTec, Sequoia Capital China and Juno Therapeutics, Inc.

J

JW Therapeutics 药明巨诺 raised $90M on March 7, 2018

Investors: Temasek, Sequoia Capital China, Yuanming Capital, WuXi AppTec and Juno Therapeutics, Inc.

E

Editas Medicine raised $47M on May 27, 2015

Investors: Juno Therapeutics, Inc.

Funding rounds raised

Total raised

$134M

from 8 investors over 8 rounds

J

Juno Therapeutics, Inc. raised $134M on August 5, 2014

Investors: Bezos Expeditions, Alaska Permanent Fund Corporation, Venrock and ARCH Venture Partners

J

Juno Therapeutics, Inc. raised $56M on April 24, 2014

Investors: Bezos Expeditions and Venrock

J

Juno Therapeutics, Inc. raised $120M on December 3, 2013

Investors: ARCH Venture Partners and Alaska Permanent Fund Corporation

FAQ